Frontlight ResearchEarly access
Taking peoplePhase 3
Safety and clinical parameter assessment of self-infusion therapy with Prolastin® in patients with severe AATD
Key facts
- Who runs it
- Grifols S.A.
- Where
- Germany7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 33 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Signed written informed consent obtained prior to any study-related procedure
- At least 18 years of age
- Able to understand and read German at a level sufficient to comprehend patient documents, including the informed consent, instruction materials and questionnaires. Note: Assistance for any required writing tasks can be provided by the caregiver
- A documented diagnosis of severe Alpha-1 Antitrypsin Deficiency
- Treatment with Prolastin® for at least 3 months with documented good treatment tolerability
- Ability and willingness to learn self-infusion and perform infusions at home or being accompanied by a third person (i.e. caregiver), who has the ability and willingness to learn and perform infusions without HCP supervision (after appropriate training). Note: For patients requiring a caregiver, the availability of a suitable caregiver must be ensured in order to be eligible for inclusion. For patients who perform the self-infusion themselves, the availability of an emergency contact, i.e. a person who is willing and able to be present and monitor the patient during every self-infusion throughout the main study period, must be ensured in order to be eligible for inclusion
- Having access to and being able to use (incl. reading and typing) a functional electronic device that enables phone calls and video calls (for remote calls from the study site or home-care study nurses) and access to an internet browser (for completion of the questionnaires)
- Suitable veins for venepuncture, according to the investigator’s discretion
- Life expectancy of over 3 years
Who cannot take part
- Occurrence of serious adverse drug reactions due to Prolastin® infusion in the last 3 months prior to V0
- Patients who have undergone lung transplantation
- Participation in another clinical study with investigational medicinal product within the last 3 months prior to baseline visit or simultaneous participation in another clinical study
- Contraindications as listed in the current SmPC: a) Individuals with selective immunoglobulin A (IgA) deficiency b) Known hypersensitivity against human Alpha-1 Proteinase Inhibitor or to any of the other ingredients in the formulation or component of the container
- Patients with psychiatric illnesses, imprisoned persons, persons admitted to nursing homes, persons under legal guardianship and persons not able to express their consent (e.g. due to mental impairment)
- Current smokers
- Patients with venous access via port
- Breastfeeding or pregnant women
This trial is currently available in Germany.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the safety of self-infusion therapy with Prolastin® in patients with severe AATD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin (AATD) deficiency. The “Sunshine Study”
- Record updated
- 6 October 2026